Journal article icon

Journal article

Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults.

Abstract:

Respiratory syncytial virus (RSV) infection causes respiratory disease throughout life, with infants and the elderly at risk of severe disease and death. RSV001 is a phase 1 (first-in-man), open-label, dose-escalation, clinical trial of novel genetic viral-vectored vaccine candidates PanAd3-RSV and modified vaccinia virus Ankara (MVA)-RSV. The objective of RSV001 is to characterise the (primary objective) safety and (secondary objective) immunogenicity of these vaccines in healthy younger and...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1136/bmjopen-2015-008748

Authors


Scarselli, E More by this author
Vitelli, A More by this author
Expand authors...
Publisher:
BMJ Publishing Group Publisher's website
Journal:
BMJ open Journal website
Volume:
5
Issue:
10
Pages:
e008748
Publication date:
2015-10-28
DOI:
EISSN:
2044-6055
Pubs id:
pubs:580643
URN:
uri:de950d85-8691-4d6b-9f4c-d3c6feac94af
UUID:
uuid:de950d85-8691-4d6b-9f4c-d3c6feac94af
Local pid:
pubs:580643
Language:
English
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP